FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person – Malik Shahzad (Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.			2. Issuer Name an Iterum Therapeu	tics plc [I]	ſRM]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 					
			3. Date of Earliest 7 05/30/2018	ransaction	(Mon	th/Day/Ye	ar)	Officer (give title below) Other (specify below)					
(Street) DUBLIN, L2 2			4. If Amendment, D	ate Origina	l File	d(Month/Day	/Year)	6. Individual or Joint/Group Filing(C _X_Form filed by One Reporting Person Form filed by More than One Reporting Per		Line)			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)	tion	4. Securit (A) or Dis (Instr. 3, 4)	sposed c	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	 6. Ownership Form: Direct (D) 	 Nature of Indirec Beneficia Ownershi 		
			(Wohll/Day/Tear)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)			
Ordinary Shares		05/30/2018		С		13,921	А	<u>(1)</u>	13,921	I	By Advent Life Sciences LLP ⁽²⁾		
Ordinary Shares		05/30/2018		С		7,771	A	<u>(3)</u>	21,692	I	By Advent Life Sciences LLP ⁽²⁾		
Ordinary Shares		05/30/2018		Р		8,144	A	\$ 13	29,836	I	By Advent Life Sciences LLP ⁽²⁾		
Ordinary Shares		05/30/2018		С		391,147	A	<u>(1)</u>	391,147	I	By Advent Life Sciences Fund II LP (4)		
Ordinary Shares		05/30/2018		С		218,338	A	<u>(3)</u>	609,485	I	By Advent Life Sciences Fund II LP		
Ordinary Shares		05/30/2018		Р		228,840	А	\$ 13	838,325	I	By Advent Life Sciences Fund II LP		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1474 (9-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, cans, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. N	umber of	6. Date Exer	cisable	7. Title and	l Amount	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	ion	Der	vative	and Expirati	on Date	of Underly	ing	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Secu	urities	(Month/Day	/Year)	Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Acq	uired (A)			(Instr. 3 an	d 4)	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					or D	isposed						Owned	Security:	(Instr. 4)
	Security					of (l	D)						Following	Direct (D)	
						(Ins	tr. 3, 4,						Reported	or Indirect	
						and	5)						Transaction(s)	(I)	
											Amount	1	(Instr. 4)	(Instr. 4)	
								Date	Expiration	T .4	or				
								Exercisable	Date	Title	Number				
				Code	V	(A)	(D)				of Shares				
															By
															5

Series B- 1 Preferred Shares	<u>(1)</u>	05/30/2018	С	13,92	1 (1)	<u>(5)</u>	Ordinary Shares	13,921	\$ 0	0	Ι	Advent Life Sciences LLP (2)
Series B- 2 Preferred Shares	(3)	05/30/2018	С	7,77	<u>(3)</u>	<u>(5)</u>	Ordinary Shares	7,771	\$ 0	0	Ι	By Advent Life Sciences LLP (2)
Series B- 1 Preferred Shares	(1)	05/30/2018	С	391,1	47 (1)	(5)	Ordinary Shares	391,147	\$ 0	0	I	By Advent Life Sciences Fund II LP (4)
Series B- 2 Preferred Shares	(3)	05/30/2018	С	218,3	38 (3)	(5)	Ordinary Shares	218,338	\$ 0	0	Ι	By Advent Life Sciences Fund II LP (4)

Reporting Owners

	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Malik Shahzad C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	Х								

Signatures

/s/ Shahzad Malik	05/30/2018
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

(2) Securities are held by Advent Life Sciences LLP ("Advent"). The Reporting Person is a general partner of Advent, and disclaims beneficial ownership of the shares held by Advent (2) except to the extent of his indirect pecuniary interest therein.

(3) The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

(4) Securities are held by Advent Life Sciences Fund II LP. Advent is the general partner of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent.
 (4) The Reporting Person disclaims beneficial ownership of the shares held by Advent Life Sciences Fund II LP except to the extent of his indirect pecuniary interest therein.
 (5) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.